Literature DB >> 28759461

Lasers for pelvic floor dysfunctions: is there evidence?

Patrick Lang1, Mickey Karram.   

Abstract

PURPOSE OF REVIEW: The purpose of this review is to discuss the available energy sources used in the vaginal canal that are currently being promoted for certain pelvic floor conditions and explore the body of peer-reviewed literature supporting their use. RECENT
FINDINGS: The majority of research has focused on the use of fractional CO2 laser treatment for genitourinary syndrome of menopause (GSM). Most of these studies are nonrandomized prospective studies, but their data consistently shows an improvement in symptoms without significant side effects.
SUMMARY: Vaginal laser treatment for GSM is of particular interest to gynecologists as it provides patients with a history of estrogen receptor positive breast cancer, thromboembolic event, or other contraindication to hormone therapy, an effective treatment option. Currently, we are in the early stages of scientific investigation into the use of lasers in the treatment of pelvic floor dysfunction, but the emerging data is encouraging. The existing data is limited to mostly observational studies with additional quality randomized controlled trials and sham studies needed to ensure that physicians are providing the optimum evidence-based treatments to their patients. At the present time there is insufficient data to promote these therapies for stress incontinence, vaginal tightening, or other pelvic floor abnormalities.

Entities:  

Mesh:

Year:  2017        PMID: 28759461     DOI: 10.1097/GCO.0000000000000399

Source DB:  PubMed          Journal:  Curr Opin Obstet Gynecol        ISSN: 1040-872X            Impact factor:   1.927


  3 in total

Review 1.  IUGA committee opinion: laser-based vaginal devices for treatment of stress urinary incontinence, genitourinary syndrome of menopause, and vaginal laxity.

Authors:  S Abbas Shobeiri; M H Kerkhof; Vatche A Minassian; Tony Bazi
Journal:  Int Urogynecol J       Date:  2018-12-06       Impact factor: 2.894

2.  Ablative dual-phase Erbium:YAG laser treatment of atrophy-related vaginal symptoms in post-menopausal breast cancer survivors omitting hormonal treatment.

Authors:  A R Mothes; M Runnebaum; I B Runnebaum
Journal:  J Cancer Res Clin Oncol       Date:  2018-02-27       Impact factor: 4.553

3.  The efficacy of erbium-doped yttrium aluminum garnet (Er:YAG) laser in the treatment of decreased sexual sensation: a randomized, placebo-controlled trial.

Authors:  Angkana Sathaworawong; Woraphong Manuskiatti; Chayawat Phatihattakorn; Chanida Ungaksornpairote; Janice Natasha Ng
Journal:  Lasers Med Sci       Date:  2021-04-01       Impact factor: 3.161

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.